Share >  
Share
Share on Tumblr

Us Fda Inspection

News »

   latest by relevance
Ranbaxy whistleblower pockets $48.5mn for settlement
May 15, 2013 at 19:19 | Source: CNBC-TV18
CNBC-TV18s Archana Shukla takes a closer look at Dinesh Thakur, the man who blew the whistle on Ranbaxy, and kicked off a legal battle that other generic drug makers will take notes from
Ranbaxy pleads guilty to felony; agrees to pay USD 500m
May 14, 2013 at 18:28 | Source: CNBC-TV18
In a settlement with the US FDA at the US department of Justice, Ranbaxy has pleaded guilty to felony charges. This is a culmination of the consent degree that the company had signed in end-2011 with the US Food and Drug Administration.
Ranbaxy shrugs off US lawsuit settlement; ends up 4%
May 14, 2013 at 18:11 | Source: Moneycontrol.com
Ranbaxy Labs shares recovered from early losses and ended up 3.6 percent on NSE on Tuesday. The company has agreed to settle all alleged civil violations with the US and its US arm is also pleading guilty to criminal charges related to Food, Drugs act.
Ranbaxy whistleblower Thakur richer by Rs 266cr; speaks out
May 14, 2013 at 11:50 | Source: Moneycontrol.com
Dinesh Thakur served as the whistleblower in this case and is the former Ranbaxy Director and Global Head, Research Information & Portfolio Management. Thakur is entitled to Rs 266 crore as the whistleblower in the case, the US Justice Department said.
Ranbaxy shrs fall on USD 500mn US lawsuits settlement
May 14, 2013 at 09:31 | Source: Moneycontrol.com
Ranbaxy said its US arm is pleading guilty to criminal charges related to violation of the Food, Drugs and Cosmetics Act and the company. owned by Japan's Daiichi Sankyo, will now pay USD 500 million to settle all the civil, criminal lawsuits.
Glenmark: Environment challenging, see 20% growth in FY14
May 08, 2013 at 11:14 | Source: CNBC-TV18
Pharma major Glenmark says the operating environment is challenging given the slowdown in India and longer time taken by the US drug regulator for product approvals. It is expecting a 20 percent revenue growth in FY14.

Videos »
Ranbaxy whistleblower pockets $48.5mn for settlement
Ranbaxy pleads guilty to felony; agrees to pay USD 500m
Glenmark: Environment challenging, see 20% growth in FY14
US Court rejects class action suit plea against Ranbaxy
Alembic sees 1% rise in EBITDA on antidepressant drug nod
more »

Photos »

  /  
News across the web »
Indian drug firms okay with US law on enhanced global inspection
The Indian generic drug industry is generally receptive to the proposed US law on medicine even though it seeks to enhance US-FDA inspection of the
Jun 24, 2012 at 16:00 | Source: NDTV Profit
Indian drug firms okay with US law on enhanced inspectionOn brighter side, the clearances will be faster to enable expeditious exports of the generics
The Indian generic drug industry is generally receptive to the proposed US law on medicine even though it seeks to enhance US-FDA inspection of the manufacturing facilities globally for a fee. Industr...
Jun 24, 2012 at 15:47 | Source: Business Standard
Divi's Laboratories: Hold
May 26, 2012: Investors can retain their holdings in the stock of Divi's Laboratories. An impressive financial performance and stronger demand drivers make the stock an attractive long-term bet. A re...
May 26, 2012 at 22:27 | Source: The Hindu BusinessLine
more »
Interact & exchange stock tips & market info »

Web Messenger

Platinum Member

166839 Followers

News Now  

Source:NDTV Profit - The Indian generic drug industry is generally rec...

10.36 AM Jun 25th 2012

Web Messenger

Platinum Member

166839 Followers

News Now  

Source:Business Standard - The Indian generic drug industry is general...

10.31 AM Jun 25th 2012

MMB Messenger

Platinum Member

171692 Followers

News Now  

The Indian generic drug industry is generally receptive to the propose...

12.40 PM Jun 24th 2012

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window